:新的进展
Solomon L Moshé1, Emilio Perucca2, Philippe Ryvlin3
1Saul R Korey Department of Neurology, Dominick P Purpura Department of Neuroscience and Department of Pediatrics, Laboratory of Developmental Epilepsy, Montefiore/Einstein Epilepsy Management Center, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, NY, USA.
Lancet (London, England)
|September 28, 2014
概括
影响全球数以百万计的人,导致残疾和高成本. 尽管在理解和治疗方面取得了进展,但许多患者仍然对治疗有抗性,这凸显了护理和研究中的关键差距.
科学领域:
- 神经学 神经学
- 临床医学 临床医学
- 公共卫生 公共卫生
背景情况:
- 影响全球6500万人,在残疾,死亡率,并发性疾病,耻辱和经济负担方面带来了重大挑战.
- 近几十年来,人们在了解的病理生理学和预后因素方面取得了进展.
- 这导致了的更新定义,诊断标准和分类系统.
研究的目的:
- 审查当前管理的现状,并确定持续存在的挑战.
- 突出了解和治疗方面的进步,同时承认尚未满足的需求.
主要方法:
- 对研究和临床实践近期进展的文献综述.
- 对抗药物和外科手术治疗结果的分析.
- 评估现有的知识,诊断,治疗和患者支持方面的差距.
主要成果:
- 尽管20年来抗药物的使用量大幅增加,但大约三分之一的患者表现出耐药性.
- 手术为一半以上的患者提供了显著的发作自由,但未得到充分利用.
- 在知识,诊断,治疗,宣传,教育,立法和研究方面仍然存在持续的差距.
结论:
- 在治疗,特别是耐药病例方面,仍然存在重大挑战.
- 目前的治疗方式,包括手术,并没有达到所有符合条件的患者.
- 迫切需要采取协调一致的行动,以应对治疗和研究中的多方面的挑战.
相关概念视频
Epilepsy and Seizures: Overview
1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Epilepsy ll: Types
24
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
24
Seizures l: Introduction
27
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
27
Seizures: Classification
2.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
Seizures ll: Types
23
Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
23
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K


